Market Pulse
Daily · Sep 30, 2026 · data.go.kr + ECOS
KOSPI
6,838.04
-32.77 (-0.48%)
KOSDAQ
855.91
+6.11 (+0.72%)
KOSPI 200
1,081.82
-6.33 (-0.58%)
USD/KRW
1,352.80
326030KOSPI·Aug 07, 2026
Solid earnings; adding a second product could unlock further upside
Mirae Asset Securities published a company analysis report on SK biopharmaceuticals Co., Ltd. (326030) titled "Solid earnings; adding a second product could unlock further upside".
Summary
Covers SK biopharmaceuticals Co., Ltd. (326030).
Covered stock
More on 326030
Two concerns addressed; focus now turns to RISE3 dataMirae Asset Securities · Aug 27, 2026Initiating Coverage: Xcopri’s Run; Securing New Growth Engines is NextKB Securities · May 27, 2026Strong 1Q26 earnings outlook vs. full-year cost pressuresMirae Asset Securities · Feb 09, 2026Strong 2Q25 results ease concernsMirae Asset Securities · Aug 06, 2025Concerns are overblownMirae Asset Securities · May 13, 2025Leading the wayMirae Asset Securities · Feb 07, 2025